跳至主要内容
临床试验/ACTRN12617000073303
ACTRN12617000073303终止2 期

Perampanel for the prevention of glioma associated seizures – efficacy and safety: a pilot phase II randomised controlled trial

Melbourne Health0 个研究点目标入组 40 人开始时间: 2017年1月13日最近更新:
适应症

试验速览

阶段
2 期
状态
终止
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • Pre-operative phase (ie inclusion for 7T MRI)
  • 1. 18 – 80 years
  • 2. Radiological diagnosis of a supratentorial WHO grade II-III glioma
  • 3. Planned surgical resection or biopsy of lesion
  • 4. 3T MRI performed as clinical standard of care
  • 5. Able to give informed consent
  • 6. No pre-operative seizure
  • Post-operative phase (ie inclusion for treatment intervention)
  • 1. 18-80 years
  • 2. Diagnosis of WHO grade II-III glioma
  • 3. Less than 3 weeks from date of glioma resection or biopsy
  • 4. No seizures prior to randomisation

排除标准

  • 1. Previous non-tumour related neurosurgical procedures (excluding biopsy of glioma)
  • 2. Pre-operative chemotherapy or radiotherapy
  • 3. Receiving >1000mg daily of levetiracetam or multiple concurrent anti-epileptic drugs at time of randomization
  • 4. Contraindication to 7T MRI
  • 5. Significant risk factors for non-tumour associated epilepsy
  • - Previously diagnosed epilepsy (excluding benign childhood epilepsies)
  • - Additional epileptogenic intra-cranial pathology (including intra-cranial complications from glioma resection)
  • 6. History of major psychiatric morbidity (such as psychiatric illness requiring hospitalisation or history of psychosis, major depression or suicidality) within the last 2 years
  • 7. Pregnant or breast-feeding
  • 8. Excessive alcohol or recreational drug use

研究者

相似试验